Abbonarsi

Short Hairpin Ribonucleic Acid Constructs Targeting Insulin-like Growth Factor Binding Protein-3 Ameliorates Diabetes Mellitus-related Erectile Dysfunction in Rats - 31/01/13

Doi : 10.1016/j.urology.2012.10.045 
Zhonghua Yang a, Zhangyan Zhou b, Xinghuan Wang a, , Mou Peng a, Haihong Zhou a, Zhe Meng a, Dong Chen a, Yongzhi Wang a
a Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China 
b First Affiliated Hospital of Yangtze University, Jingzhou, HuBei, China 

Reprint requests: Xinghuan Wang, M.D., Ph.D., Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071 China.

Abstract

Objective

To investigate the expression of insulin-like growth factor binding protein-3 (IGFBP-3) in penile cavernous of streptozotocin (STZ)-induced DM rats and whether downregulation of IGFBP-3 by intracavernosal injection of short hairpin ribonucleic acid (shRNA) targeting IGFBP-3 could improve the erectile function in DM rats.

Materials and Methods

Diabetes was induced in rats by intraperitoneal injection of STZ, and the expression of IGFBP-3 in the penile tissue of adult normal and DM male rats was assayed using reverse transcriptase-polymerase chain reaction and Western blot. Next, shRNA-targeting IGFBP-3 and a scramble sequence were injected into the penile corpora cavernosa of DM rats. At 12 weeks after shRNA-IGFBP-3 administration, the intracavernous pressure in response to electrical stimulation of the cavernous nerves was evaluated. The expression of IGFBP-3 was assayed by Western blot. The concentration of cyclic guanosine monophosphate in the corpus cavernosum was assayed by enzyme-linked immunosorbent assay.

Results

At 12 week after intraperitoneal administration of STZ, IGFBP-3 expression had increased in the penis of the DM rat (P <.05) compared with that of the normal control rats. Among the DM rats, IGFBP-3 expression at the messenger RNA and protein level was significantly inhibited 12 weeks after intracavernous administration of IGFBP-3 shRNA (P <.01). At 12 weeks after shRNA-IGFBP-3 injection, intracavernosal pressure was significantly increased in response to cavernous nerve stimulation (P <.05), and an increase in the concentration of cyclic guanosine monophosphate in the corpus cavernous tissue (P <.01) was detected compared with the “randomer” shRNA treatment group.

Conclusion

Gene transfer of shRNA-IGFBP-3 could improve erectile function in STZ-induced DM rats by an increase in the cyclic guanosine monophosphate concentration in cavernous tissue.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Z. Yang and Z. Zhou contributed to this study equally.
 Financial Disclosure: The authors declare that they have no relevant financial interests.
 Funding Support: This study was supported by the National Natural Science Foundation of China (grant 81172734) and Independent Research Projects of Wuhan University (grant 111086).


© 2013  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 81 - N° 2

P. 464.e11-464.e16 - febbraio 2013 Ritorno al numero
Articolo precedente Articolo precedente
  • Establishment and Characterization of a new Human Extragonadal Germ Cell Line, SEM-1, and its Comparison With TCam-2 and JKT-1
  • Sarah M. Russell, Melissa G. Lechner, Anusuya Mokashi, Carolina Megiel, Julie K. Jang, Clive R. Taylor, Leendert H.J. Looijenga, Christopher A. French, Alan L. Epstein
| Articolo seguente Articolo seguente
  • Comparison of Three Types of Stress Urinary Incontinence Rat Models: Electrocauterization, Pudendal Denervation, and Vaginal Distension
  • Sung-Hoo Hong, Shuyu Piao, In Gul Kim, Ji Young Lee, Hyuk Jin Cho, Sae Woong Kim, Tae-Kon Hwang, Ji Youl Lee

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.